Celularity (CELU) Other Non-Current Assets (2020 - 2025)
Celularity (CELU) posted quarterly Other Non-Current Assets of $10.2 million for Q4 2025, up 3676.67% year-over-year from $270000.0 in Q4 2024, and up 0.61% quarter-over-quarter from $10.1 million in Q3 2025.
Celularity (CELU) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Celularity (CELU) has reported Other Non-Current Assets for 6 consecutive years, with $10.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 3676.67% year-over-year to $10.2 million; the TTM figure through Dec 2025 stood at $10.2 million (up 3676.67% YoY), while the FY2025 annual figure was $10.2 million, up 3676.67% from the prior year.
- Other Non-Current Assets rose to $10.2 million in Q4 2025 per CELU's latest filing, from $10.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $14.8 million in Q4 2021 and bottomed at $254000.0 in Q1 2025.
- Historically, Other Non-Current Assets has averaged $6.8 million across 5 years, with a median of $10.0 million in 2023.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets tumbled 97.8% — and 2025, when it jumped 3676.67%.
- Celularity's Other Non-Current Assets stood at $14.8 million in 2021, then changed by 0.0% to $14.8 million in 2022, then tumbled by 33.03% to $9.9 million in 2023, then sank by 97.28% to $270000.0 in 2024, then surged by 3676.67% to $10.2 million in 2025.
- Business Quant data shows CELU's Other Non-Current Assets at $10.2 million in Q4 2025, $10.1 million in Q3 2025, and $10.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 65.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 104.44 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 62.96 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 202.31 Mn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | 10.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.20 Mn |
| Sep 30, 2025 | 10.14 Mn |
| Jun 30, 2025 | 10.07 Mn |
| Mar 31, 2025 | 254,000.00 |
| Dec 31, 2024 | 270,000.00 |
| Sep 30, 2024 | 10.16 Mn |
| Jun 30, 2024 | 10.09 Mn |
| Mar 31, 2024 | 327,000.00 |
| Dec 31, 2023 | 9.94 Mn |
| Sep 30, 2023 | 354,000.00 |
| Jun 30, 2023 | 326,000.00 |
| Mar 31, 2023 | 352,000.00 |
| Dec 31, 2022 | 14.84 Mn |
| Sep 30, 2022 | 401,000.00 |
| Jun 30, 2022 | 14.83 Mn |
| Mar 31, 2022 | 810,000.00 |
| Dec 31, 2021 | 14.84 Mn |
| Sep 30, 2021 | 14.72 Mn |
| Dec 31, 2020 | 481,000.00 |